Abstract:Pulmonary hypertension (PH) is a pulmonary vascular disease characterized by a high mortality rate. Pulmonary arterial endothelium cells (PAECs) serve as a primary sensor of various environmental cues, such as shear stress and hypoxia, but PAEC dysfunction may trigger vascular remodeling during the onset of PH. This study was aimed to illustrate the role of SIRT7 in endothelial dysfunction during PH, and explore the potential therapeutic strategy for PH. SIRT7 levels were measured in human and murine experimental PH samples. Bioinformatic analysis, immunoprecipitation, and deacetylation assay was used to identify the association between SIRT7 and Krüpple-like factor 4 (KLF4), a key transcription factor essential for EC homeostasis. Sugen5416+hypoxia (SuHx)-induced PH mouse models and cell cultures were used for the study of the therapeutic effect of SIRT7 for PH. SIRT7 level was significantly reduced in lung tissues and PAECs from PH patients and the SuHx-induced PH mouse model as compared with healthy controls. Pulmonary endothelium-specific depletion of Sirt7 increased right ventricular systolic pressure and exacerbated right ventricular hypertrophy in the SuHx-induced PH model. At the molecular level, we identified KLF4 as a downstream target of SIRT7, which deacetylated KLF4 at K228 and inhibited the ubiquitination-proteasome degradation. Thus, the SIRT7/KLF4 axis maintained PAEC homeostasis by regulating proliferation, migration, and tube formation. PAEC dysfunction was reversed by adeno-associated virus type 1 vector mediated endothelial overexpression of Sirt7 or supplementation with NAD + intermediate nicotinamide riboside which activated Sirt7; both approaches successfully reversed PH phenotypes. The SIRT7/KLF4 axis ensures PAEC homeostasis, and pulmonary endothelium-specific SIRT7 targeting might constitute a PH therapeutic strategy. Pulmonary endothelial cell dysfunction is pivotal in vascular remodeling process during pulmonary hypertension pathogenesis. We identified a SIRT7/KLF4 axis essential for pulmonary endothelial homeostasis, however compromised in pulmonary hypertension patients and animal models. Pulmonary endothelium-specific Sirt7 gene delivery or treatment with NAD + precursor reversed PH phenotypes, providing a new therapeutic strategy for PH. In normal pulmonary artery endothelial cells, SIRT7 deacetylates KLF4 at K228 to maintain its protein stability, promotes endothelial homeostasis and pulmonary vascular function. During pulmonary hypertension pathogenesis, SIRT7 was reduced, resulted in increased acetylation of KLF4, promoting its ubiquitination and degradation in pulmonary endothelial cells. The ultimate endothelial dysfunction contributes to vascular remodeling and accelerated pulmonary hypertension.

Sirtuin 7 ameliorates cuproptosis, myocardial remodeling and heart dysfunction in hypertension through the modulation of YAP/ATP7A signaling

Sirtuin 7 mitigates renal ferroptosis, fibrosis and injury in hypertensive mice by facilitating the KLF15/Nrf2 signaling

Sirtuin 7 serves as a promising therapeutic target for cardiorenal diseases

The Sirtuin 6 Prevents Angiotensin II-mediated Myocardial Fibrosis and Injury by Targeting AMPK-ACE2 Signaling

SIRT2 inhibition protects against cardiac hypertrophy and heart failure

Endothelium-specific SIRT7 targeting ameliorates pulmonary hypertension through KLF4 deacetylation

Synaptotagmin-7 mediates cardiac hypertrophy by targeting autophagy

Sirt7 Contributes to Myocardial Tissue Repair by Maintaining Transforming Growth Factor-β Signaling Pathway

Endothelial SIRT6 Is Vital to Prevent Hypertension and Associated Cardiorenal Injury Through Targeting Nkx3.2-GATA5 Signaling

Roles of SIRT3 in Heart Failure: from Bench to Bedside.

SIRT7 Regulates the Vascular Smooth Muscle Cells Proliferation and Migration via Wnt/ β-Catenin Signaling Pathway

Sirt7 protects against vascular calcification via modulation of reactive oxygen species and senescence of vascular smooth muscle cells

SIRT1 Functions As an Important Regulator of Estrogen-Mediated Cardiomyocyte Protection in Angiotensin II-Induced Heart Hypertrophy

Quercetin Attenuates Cardiac Hypertrophy by Inhibiting Mitochondrial Dysfunction Through SIRT3/PARP-1 Pathway

Cardioprotective Effects of SIRT6 in a Mouse Model of Transverse Aortic Constriction-Induced Heart Failure.

SIRT1 exerts anti-hypertensive effect via FOXO1 activation in the rostral ventrolateral medulla

Abstract 9553: Sirtuin1 Aggravates Hypertrophic Heart Failure Caused by Pressure Overload Via Shifting Energy Metabolism

SZC-6, a Small-Molecule Activator of SIRT3, Attenuates Cardiac Hypertrophy in Mice

SIRT2 Acts As a Cardioprotective Deacetylase in Pathological Cardiac Hypertrophy.

Sirt4 accelerates Ang II-induced pathological cardiac hypertrophy by inhibiting manganese superoxide dismutase activity.

Cardiac-Specific Overexpression of Silent Information Regulator 1 Protects Against Heart and Kidney Deterioration in Cardiorenal Syndrome via Inhibition of Endoplasmic Reticulum Stress.